Search details
1.
Ovarian cancer mutational processes drive site-specific immune evasion.
Nature
; 612(7941): 778-786, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36517593
2.
Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Gynecol Oncol
; 182: 32-38, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38246044
3.
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Gynecol Oncol
; 182: 75-81, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38262242
4.
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol
; 186: 104-109, 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38640773
5.
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Gynecol Oncol
; 180: 35-43, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38041901
6.
Redefining the standard of care for low-grade serous ovarian cancer.
Clin Adv Hematol Oncol
; 22(5): 205-226, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38805312
7.
Understanding social needs screening and demographic data collection in primary care practices serving Maryland Medicare patients.
BMC Health Serv Res
; 24(1): 448, 2024 Apr 10.
Article
in English
| MEDLINE | ID: mdl-38600578
8.
The highs and lows of serous ovarian cancer.
Cancer
; 129(17): 2613-2620, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37366225
9.
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Cancer
; 129(13): 2004-2012, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-36951509
10.
Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
Gynecol Oncol
; 169: 85-90, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36521353
11.
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Gynecol Oncol
; 171: 23-30, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36804618
12.
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 176: 69-75, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37454565
13.
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
Gynecol Oncol
; 170: 46-53, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36621269
14.
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol
; 170: 93-101, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36669327
15.
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol
; 174: 34-41, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37149903
16.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer
; 33(9): 1331-1344, 2023 09 04.
Article
in English
| MEDLINE | ID: mdl-37591609
17.
Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer.
Int J Gynecol Cancer
; 2023 Dec 07.
Article
in English
| MEDLINE | ID: mdl-38088180
18.
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Gynecol Oncol
; 164(1): 12-17, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34763937
19.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
J Natl Compr Canc Netw
; 20(9): 972-980, 2022 09.
Article
in English
| MEDLINE | ID: mdl-36075393
20.
Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Curr Oncol Rep
; 24(11): 1549-1555, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35962920